General Usage: The recommended dose of tocilizumab for adults is 8mg/kg, intravenously infused once every 4 weeks, and can be used in combination with MTX or other DMARDs. When abnormal liver enzymes, decreased neutrophil count, or decreased platelet count occur, the dose of tocilizumab can be reduced to 4 mg/kg. Tocilizumab needs to be diluted to 100ml with 0.9 sterile saline by a medical professional using aseptic methods. It is recommended that the intravenous infusion time of tocilizumab is more than 1 hour. For patients weighing more than 100kg, the recommended infusion dose should not exceed 800mg per time (see Pharmacokinetics section). Recommendations for dose adjustment: (See Precautions for Laboratory Tests) Measures for abnormal liver enzyme laboratory test values ??gt; 1 to 3 times the upper limit of normal (ULN) Appropriately adjust the dose of combined DMARDs; If the aminotransferase is within this range If the increase continues, the dose of tocilizumab can be reduced to 4 mg/kg or the medication can be discontinued until the aminotransferase returns to normal levels; if clinically permitted, tocilizumab can be restarted at a dose of 4 mg/kg or 8 mg/kg. anti. gt; 3 to 5 times ULN (repeated testing is required to confirm). Discontinue tocilizumab until recovery to >3 times ULN, then proceed as recommended above for >1 to 3 times ULN; if increase continues to >3 times ULN, discontinue tocilizumab . >5 times ULN Discontinue tocilizumab administration. Absolute neutrophil count (ANC) decrease Laboratory test value (cells × 109/L) Measures ANC gt; 1. Maintain the original dose. ANC 0.5～1: Discontinue the administration of tocilizumab; when the ANC returns to >1×109/L, if clinically permitted, tocilizumab can be restarted at a dose of 4 mg/kg and can be increased to 8 mg/kg. ANC lt; 0.5 Discontinue tocilizumab. The platelet count decreases in the laboratory test value (cells × 103/ml). Measures 50 to 100. Discontinue the administration of tocilizumab; when the platelet count returns to >100 × 103/ml, if clinically permitted, a dose of 4 mg/kg can be used. Restart tocilizumab and increase to 8 mg/kg. lt; 50 Stop giving tocilizumab. Specific Medication Instructions Patients with Renal Impairment: No dose adjustment is required in patients with mild renal impairment (see Pharmacokinetics in Special Populations section). Tocilizumab has not been studied in patients with moderate to severe renal impairment. Patients with Hepatic Impairment: The safety and effectiveness of tocilizumab have not been studied in patients with hepatic impairment (see the General Precautions section). Special Instructions for Use, Operation and Disposal Before use, the injected drugs should be visually inspected for particles or color changes. Only when the drug solution is clear to translucent, colorless to light yellow, and has no particles visible to the naked eye, it can be used for infusion. Calculate the required volume of tocilizumab solution based on body weight, draw an equal amount of normal saline from a 100ml sterile pyrogen-free normal saline infusion bag and discard it, then inject the calculated required tocilizumab solution into the infusion bag. Allow to be diluted to a final volume of 100 ml. Mix the solution and invert carefully to avoid air bubbles. Disposal of unused or expired drugs: The release of drugs into the environment should be minimized. Medications should not be disposed of with wastewater and should not be thrown away with household waste. If a local "recycling system" has been established, please use this system for processing. Prepared injection: The physical and chemical properties of tocilizumab injection prepared with 0.9 normal saline can remain stable for 24 hours at 30°C. From a microbiological point of view, the prepared liquid should be used immediately. If it cannot be used immediately, the user should be responsible for controlling the storage time and storage conditions, that is, no more than 24 hours at 2~8°C.